Loading
Women whose HER2-positive breast cancer was still present at surgery after chemotherapy and trastuzumab had half the risk of relapse if their post-surgery treatment was switched to the antibody-drug conjugate T-DM1 instead of continuing trastuzumab.
Open-label phase 3 trial of 1,486 patients with HER2-positive early breast cancer who had residual invasive disease in the breast or axilla after neoadjuvant taxane- and trastuzumab-based therapy, randomised to 14 cycles of adjuvant trastuzumab emtansine (T-DM1) or trastuzumab. Primary endpoint was invasive disease-free survival.
Three-year iDFS was 88.3% vs 77.0% (HR 0.50). Later follow-up confirmed an overall survival benefit. It established the response-adapted strategy: treat before surgery, then escalate only for those with residual disease.
HER2-positive breast cancer is now routinely treated before surgery so that the pathology result can guide what comes after: patients with no residual cancer continue trastuzumab (with or without pertuzumab), while those with residual disease switch to T-DM1. This model of using the tumour's response as a test has since been copied in triple-negative and other cancers.
Shares Early HER2-positive breast cancer, Trastuzumab emtansine, Pathologic complete response (pCR), Roche / Genentech.
Shares Early HER2-positive breast cancer, Trastuzumab emtansine, Roche / Genentech, Trastuzumab.
Shares Zhi-Ming Shao, Charles E. Geyer Jr., Sibylle Loibl, Residual cancer burden (RCB).
Shares DESTINY-Breast03, Trastuzumab emtansine, HER2, HER2-positive breast cancer.
Shares Early HER2-positive breast cancer, Trastuzumab emtansine, Trastuzumab, HER2-positive breast cancer.
Shares DESTINY-Breast03, Trastuzumab emtansine, HER2, HER2-positive breast cancer.
Shares Early HER2-positive breast cancer, Trastuzumab emtansine, HER2-positive breast cancer, Antibody-drug conjugate (ADC).
Shares ADC for residual disease after KEYNOTE-522, Residual cancer burden (RCB), Pathologic complete response (pCR), Dormant cells and minimal residual disease.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/